LIAONING CHENGDA BIOTECHNOLOGY CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.45 CNY | -0.54% |
|
-3.51% | -15.56% |
| May. 20 | Wall Street Cues, Central Bank Outlooks Lift Asian Stock Markets | MT |
| Apr. 29 | Liaoning Chengda Biotechnology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
ETFs positioned on Liaoning Chengda Biotechnology Co.,Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +4.20% | - |
Liaoning Chengda Biotechnology Co Ltd is a China-based company mainly engaged in the research, production, and sales of human vaccines. The Company's main products include rabies vaccine for human use, freeze-dried rabies vaccine for human use, inactivated Japanese encephalitis vaccine for human use and freeze-dried encephalitis inactivated vaccine. The Company's products include two brands: Chengda Suda and Chengda Libao.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
27.45
CNY
Average target price
32
CNY
Spread / Average Target
+16.58%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -15.56% | 1.56B | |
| -2.31% | 90.02B | |
| -1.18% | 39.15B | |
| -15.83% | 31.71B | |
| +62.86% | 26.47B | |
| -21.68% | 14.34B | |
| -8.73% | 12.89B | |
| -15.05% | 11.18B | |
| -45.69% | 10.97B | |
| +4.94% | 8.94B |
- Stock Market
- Equities
- 688739 Stock
- Funds and ETFs Liaoning Chengda Biotechnology Co.,Ltd.
